Chicago Partners Investment Group LLC Acquires New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Chicago Partners Investment Group LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 953 shares of the medical research company’s stock, valued at approximately $218,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Farther Finance Advisors LLC raised its position in shares of IQVIA by 35.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock worth $96,000 after purchasing an additional 106 shares during the last quarter. Lebenthal Global Advisors LLC increased its position in IQVIA by 128.4% during the third quarter. Lebenthal Global Advisors LLC now owns 2,739 shares of the medical research company’s stock worth $649,000 after buying an additional 1,540 shares in the last quarter. Principal Securities Inc. raised its holdings in shares of IQVIA by 4.2% in the third quarter. Principal Securities Inc. now owns 27,649 shares of the medical research company’s stock worth $6,552,000 after acquiring an additional 1,108 shares during the last quarter. US Bancorp DE boosted its stake in shares of IQVIA by 62.2% during the third quarter. US Bancorp DE now owns 27,061 shares of the medical research company’s stock valued at $6,413,000 after acquiring an additional 10,379 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new stake in IQVIA during the 3rd quarter worth about $111,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on IQV shares. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Friday, November 1st. BTIG Research decreased their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday. UBS Group lifted their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, The Goldman Sachs Group reduced their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $259.13.

IQVIA Stock Performance

Shares of IQV stock opened at $212.96 on Wednesday. The company’s fifty day simple moving average is $232.84 and its 200-day simple moving average is $229.54. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52 week low of $190.20 and a 52 week high of $261.73. The company has a market cap of $38.65 billion, a PE ratio of 27.95, a P/E/G ratio of 2.07 and a beta of 1.51.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.